CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: NDUFC2 (ImmuneEditome ID:4718)

1. Gene summary of enriched editing regions for NDUFC2

check button Gene summary
Gene informationGene symbol

NDUFC2

Gene ID

4718

GeneSynonymsB14.5b|CI-B14.5b|HLC-1|MC1DN36|NADHDH2
GeneCytomap

11q14.1

GeneTypeprotein-coding
GeneDescriptionNADH dehydrogenase [ubiquinone] 1 subunit C2|NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 2, 14.5kDa|NADH-ubiquinone oxidoreductase subunit B14.5b|complex I subunit B14.5b|complex I-B14.5b|human lung cancer oncogene 1 protein
GeneModificationdate20230518
UniprotIDO95298;E9PM14;E9PRJ5;A0A024R5K6
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr11:78068485-78069212:-ENST00000281031.4ENSG00000151366.11NDUFC2UTR3AluSc,AluJbchr11:78068485-78069212:-.alignment
chr11:78068485-78069212:-ENST00000527806.1ENSG00000151366.11NDUFC2UTR3AluSc,AluJbchr11:78068485-78069212:-.alignment


Top

2. Tumor-specific enriched editing regions for NDUFC2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr11:78068485-78069212:-BRCAEER2.4705e-07image
ENSG00000151366.11,NDUFC2BRCAEAG2.4705e-07image
chr11:78068485-78069212:-COADEER6.4716e-03image
ENSG00000151366.11,NDUFC2COADEAG4.2474e-03image
chr11:78068485-78069212:-HNSCEER3.3905e-08image
ENSG00000151366.11,NDUFC2HNSCEAG3.3905e-08image
chr11:78068485-78069212:-KIRCEER6.1167e-04image
ENSG00000151366.11,NDUFC2KIRCEAG6.1167e-04image
chr11:78068485-78069212:-LIHCEER1.5564e-02image
ENSG00000151366.11,NDUFC2LIHCEAG1.5564e-02image
chr11:78068485-78069212:-LUADEER8.7222e-04image
ENSG00000151366.11,NDUFC2LUADEAG8.6706e-04image
chr11:78068485-78069212:-LUSCEER2.7791e-10image
ENSG00000151366.11,NDUFC2LUSCEAG2.7791e-10image
chr11:78068485-78069212:-THCAEER1.8336e-04image
ENSG00000151366.11,NDUFC2THCAEAG1.8336e-04image
chr11:78068485-78069212:-UCECEER2.1425e-02image
ENSG00000151366.11,NDUFC2UCECEAG1.9180e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr11:78068485-78069212:-ESCACliEER2.4727e-021.0193e-02-0.3792image
ENSG00000151366.11,NDUFC2ESCACliEAG2.4727e-021.0193e-02-0.3792image
ENSG00000151366.11,NDUFC2KIRCPathEAG1.9182e-061.0997e-070.2296image
chr11:78068485-78069212:-KIRCPathEER1.9182e-061.0997e-070.2296image
ENSG00000151366.11,NDUFC2THCAPathEAG8.7119e-032.5661e-020.0997image
chr11:78068485-78069212:-THCAPathEER8.7119e-032.5661e-020.0997image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for NDUFC2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr11:78068485-78069212:-DLBCEERENSG00000105327,BBC30.60563.8470e-024.1000e-050.6011imageNNBBC3B_cells_memory
chr11:78068485-78069212:-DLBCEERENSG00000164938,TP53INP1-0.59734.4388e-025.3320e-03-0.4324imageNNTP53INP1T_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V2
chr11:78068485-78069212:-UVMEERENSG00000009307,CSDE1-0.50861.2286e-031.4701e-05-0.4865imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_KRAS_SIGNALING_DN
chr11:78068485-78069212:-UVMEERENSG00000234797,RPS3AP6-0.51581.3888e-031.8073e-04-0.4274imageNNNAEosinophilsGSVA_HALLMARK_KRAS_SIGNALING_DN
chr11:78068485-78069212:-UVMEERENSG00000138604,GLCE-0.50031.9774e-033.5858e-04-0.4092imageNNNAEosinophilsGSVA_HALLMARK_KRAS_SIGNALING_DN
chr11:78068485-78069212:-UVMEERENSG00000167797,CDK2AP20.48832.5779e-031.6898e-040.4291imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_KRAS_SIGNALING_DN
chr11:78068485-78069212:-UVMEERENSG00000170088,TMEM192-0.49042.6107e-032.7506e-05-0.4728imageNNNAT_cells_follicular_helperGSVA_HALLMARK_PROTEIN_SECRETION
chr11:78068485-78069212:-UVMEERENSG00000014164,ZC3H30.48362.7821e-037.8661e-060.4997imageNNNAMast_cells_activatedGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr11:78068485-78069212:-UVMEERENSG00000225031,EIF4BP7-0.48092.8020e-031.3707e-05-0.4880imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_KRAS_SIGNALING_DN
chr11:78068485-78069212:-UVMEERENSG00000180964,TCEAL8-0.48122.8438e-031.5299e-04-0.4317imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_MYOGENESIS
chr11:78068485-78069212:-DLBCEERENSG00000105327,BBC30.60563.8470e-024.1000e-050.6011imageNNBBC3B_cells_memory
chr11:78068485-78069212:-DLBCEERENSG00000164938,TP53INP1-0.59734.4388e-025.3320e-03-0.4324imageNNTP53INP1T_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V2
chr11:78068485-78069212:-UVMEERENSG00000009307,CSDE1-0.50861.2286e-031.4701e-05-0.4865imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_KRAS_SIGNALING_DN
chr11:78068485-78069212:-UVMEERENSG00000234797,RPS3AP6-0.51581.3888e-031.8073e-04-0.4274imageNNNAEosinophilsGSVA_HALLMARK_KRAS_SIGNALING_DN
chr11:78068485-78069212:-UVMEERENSG00000138604,GLCE-0.50031.9774e-033.5858e-04-0.4092imageNNNAEosinophilsGSVA_HALLMARK_KRAS_SIGNALING_DN
chr11:78068485-78069212:-UVMEERENSG00000167797,CDK2AP20.48832.5779e-031.6898e-040.4291imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_KRAS_SIGNALING_DN
chr11:78068485-78069212:-UVMEERENSG00000170088,TMEM192-0.49042.6107e-032.7506e-05-0.4728imageNNNAT_cells_follicular_helperGSVA_HALLMARK_PROTEIN_SECRETION
chr11:78068485-78069212:-UVMEERENSG00000014164,ZC3H30.48362.7821e-037.8661e-060.4997imageNNNAMast_cells_activatedGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr11:78068485-78069212:-UVMEERENSG00000225031,EIF4BP7-0.48092.8020e-031.3707e-05-0.4880imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_KRAS_SIGNALING_DN
chr11:78068485-78069212:-UVMEERENSG00000180964,TCEAL8-0.48122.8438e-031.5299e-04-0.4317imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_MYOGENESIS

More results



Top

4. Enriched editing regions and immune related splicing for NDUFC2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr11:78068485-78069212:-
BLCAEERESENSG00000107485.11chr108058398:8058841:8063995:8064138:8069472:8069596-0.14883.6367e-022.7306e-16-0.4464imageNNGATA3NK_cells_restingGSVA_HALLMARK_INFLAMMATORY_RESPONSE
ENSG00000151366.11,NDUFC2
COADEAGIRENSG00000132313.10chr286210479:86210613:86212425:86212838-0.23563.7092e-026.5739e-11-0.4008imageNADAR;AUH;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RTCB;SAFB2;SBDS;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NANK_cells_activatedGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
ENSG00000151366.11,NDUFC2
COADEAGIRENSG00000111684.6chr126976185:6978507:6978602:69786890.23154.5112e-021.8686e-270.6194imageNACIN1;ADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184NAEosinophilsGSVA_HALLMARK_XENOBIOTIC_METABOLISM
ENSG00000151366.11,NDUFC2
COADEAGA3ENSG00000219481.6chr116567978:16568030:16567178:16567271:16567178:165673510.06373.1095e-023.6785e-310.6996imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_SPERMATOGENESIS
ENSG00000151366.11,NDUFC2
COADEAGESENSG00000167107.8chr1750463515:50463552:50463817:50463909:50464217:50464294-0.25145.7181e-035.9526e-21-0.5598imageNADAR;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184ACSF2Dendritic_cells_activatedGSVA_HALLMARK_BILE_ACID_METABOLISM
ENSG00000151366.11,NDUFC2
COADEAGA3ENSG00000123636.13chr2159397344:159397382:159395768:159395834:159395768:159397100-0.21462.5685e-026.9736e-10-0.4175imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NANeutrophilsGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
ENSG00000151366.11,NDUFC2
TGCTEAGA5ENSG00000109113.13chr1728717212:28717291:28718369:28718405:28718121:287184050.38893.4176e-048.0527e-070.4309imageNAIFM1;CNBP;DGCR8;DICER1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPK;IGF2BP1;IGF2BP2;KHDRBS2;LARP4B;LIN28;LIN28A;LIN28B;MOV10;NOP56;NOP58;NUMA1;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM10;RC3H1;RNF219;RTCB;SND1;SRSF1;SRSF3;SRSF7;TAF15;TARDBP;U2AF2;UPF1;YTHDC1;YTHDF1;ZNF184RAB34Macrophages_M2GSVA_HALLMARK_APICAL_JUNCTION
ENSG00000151366.11,NDUFC2
TGCTEAGA5ENSG00000001167.10chr641084045:41084192:41079028:41079164:41079028:410808970.33692.0480e-031.0211e-060.4289imageNADAR;AUH;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAMacrophages_M2GSVA_HALLMARK_UV_RESPONSE_DN
chr11:78068485-78069212:-
TGCTEERIRENSG00000008710.13chr162092046:2092592:2092953:20930930.42321.6806e-044.0808e-080.4570imageNNPKD1Macrophages_M2GSVA_HALLMARK_SPERMATOGENESIS
chr11:78068485-78069212:-
TGCTEERIRENSG00000100299.13chr2250627555:50627792:50627945:506281700.36941.0229e-033.9852e-060.4008imageNNNAB_cells_naiveGSVA_HALLMARK_APICAL_JUNCTION

More results



Top

5. Enriched editing regions and immune infiltration for NDUFC2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr11:78068485-78069212:-ACCEERPlasma_cells1.0784e-020.2872image
ENSG00000151366.11,NDUFC2ACCEAGPlasma_cells1.0784e-020.2872image
chr11:78068485-78069212:-BLCAEERNK_cells_resting4.9650e-070.2613image
ENSG00000151366.11,NDUFC2BLCAEAGT_cells_CD4_memory_activated8.5303e-060.2322image
chr11:78068485-78069212:-BRCAEERMacrophages_M11.6044e-120.2138image
ENSG00000151366.11,NDUFC2BRCAEAGMacrophages_M11.6044e-120.2138image
chr11:78068485-78069212:-CHOLEERT_cells_follicular_helper2.2494e-030.4995image
ENSG00000151366.11,NDUFC2CHOLEAGT_cells_follicular_helper2.2494e-030.4995image
chr11:78068485-78069212:-COADEERT_cells_CD4_memory_resting3.6982e-03-0.1848image
ENSG00000151366.11,NDUFC2COADEAGDendritic_cells_activated1.4772e-030.2016image
chr11:78068485-78069212:-ESCAEERT_cells_regulatory_(Tregs)4.6406e-03-0.2363image
ENSG00000151366.11,NDUFC2ESCAEAGT_cells_regulatory_(Tregs)4.6406e-03-0.2363image
chr11:78068485-78069212:-GBMEERT_cells_CD4_memory_resting2.4373e-030.2338image
ENSG00000151366.11,NDUFC2GBMEAGT_cells_CD4_memory_resting2.4373e-030.2338image
chr11:78068485-78069212:-HNSCEERT_cells_regulatory_(Tregs)2.9059e-03-0.1498image
ENSG00000151366.11,NDUFC2HNSCEAGT_cells_regulatory_(Tregs)2.9059e-03-0.1498image
ENSG00000151366.11,NDUFC2KICHEAGMacrophages_M02.3775e-040.4540image
chr11:78068485-78069212:-KIRCEERT_cells_CD81.0369e-040.1981image
ENSG00000151366.11,NDUFC2KIRCEAGT_cells_CD81.0369e-040.1981image
chr11:78068485-78069212:-KIRPEERNK_cells_resting1.5020e-030.1916image
ENSG00000151366.11,NDUFC2KIRPEAGNK_cells_resting6.7536e-040.2049image
ENSG00000151366.11,NDUFC2LAMLEAGMonocytes4.0507e-020.3531image
chr11:78068485-78069212:-LGGEERMacrophages_M01.1351e-03-0.1413image
ENSG00000151366.11,NDUFC2LGGEAGMacrophages_M01.1351e-03-0.1413image
chr11:78068485-78069212:-LIHCEERMacrophages_M13.2184e-040.1855image
ENSG00000151366.11,NDUFC2LIHCEAGMacrophages_M13.2184e-040.1855image
chr11:78068485-78069212:-LUADEERT_cells_CD4_memory_activated4.6092e-040.1609image
ENSG00000151366.11,NDUFC2LUADEAGT_cells_CD4_memory_activated4.1764e-040.1621image
chr11:78068485-78069212:-LUSCEERT_cells_CD4_memory_activated2.4659e-040.1769image
ENSG00000151366.11,NDUFC2LUSCEAGT_cells_CD4_memory_activated2.4659e-040.1769image
chr11:78068485-78069212:-MESOEERMonocytes1.6950e-02-0.2647image
ENSG00000151366.11,NDUFC2MESOEAGMonocytes1.6950e-02-0.2647image
chr11:78068485-78069212:-OVEERT_cells_CD84.1955e-040.2058image
ENSG00000151366.11,NDUFC2OVEAGT_cells_CD84.1265e-040.2061image
chr11:78068485-78069212:-PAADEERT_cells_CD4_naive1.8258e-030.2367image
ENSG00000151366.11,NDUFC2PAADEAGT_cells_CD4_naive1.8258e-030.2367image
chr11:78068485-78069212:-PCPGEERT_cells_CD4_memory_resting7.0465e-03-0.1986image
ENSG00000151366.11,NDUFC2PCPGEAGT_cells_CD4_memory_resting7.0465e-03-0.1986image
chr11:78068485-78069212:-PRADEERT_cells_regulatory_(Tregs)8.8204e-040.1489image
ENSG00000151366.11,NDUFC2PRADEAGT_cells_regulatory_(Tregs)8.8204e-040.1489image
chr11:78068485-78069212:-READEERB_cells_naive3.0225e-020.2273image
ENSG00000151366.11,NDUFC2READEAGB_cells_naive3.0225e-020.2273image
chr11:78068485-78069212:-SARCEERT_cells_CD82.1515e-030.1948image
ENSG00000151366.11,NDUFC2SARCEAGT_cells_CD82.1515e-030.1948image
chr11:78068485-78069212:-SKCMEERT_cells_CD86.6914e-060.2155image
ENSG00000151366.11,NDUFC2SKCMEAGT_cells_CD86.6914e-060.2155image
chr11:78068485-78069212:-STADEERDendritic_cells_activated1.8847e-020.1318image
ENSG00000151366.11,NDUFC2STADEAGDendritic_cells_activated1.9605e-020.1310image
chr11:78068485-78069212:-TGCTEERMacrophages_M21.9346e-05-0.3526image
ENSG00000151366.11,NDUFC2TGCTEAGMacrophages_M21.9346e-05-0.3526image
chr11:78068485-78069212:-THCAEERT_cells_regulatory_(Tregs)4.3036e-080.2415image
ENSG00000151366.11,NDUFC2THCAEAGT_cells_regulatory_(Tregs)4.3036e-080.2415image
chr11:78068485-78069212:-THYMEERT_cells_CD4_memory_activated4.0299e-070.4465image
ENSG00000151366.11,NDUFC2THYMEAGT_cells_CD4_memory_activated4.0299e-070.4465image
ENSG00000151366.11,NDUFC2UCECEAGPlasma_cells2.7231e-020.1694image
ENSG00000151366.11,NDUFC2UCSEAGT_cells_CD83.6148e-030.4002image
chr11:78068485-78069212:-UVMEEREosinophils5.2395e-030.3257image
ENSG00000151366.11,NDUFC2UVMEAGEosinophils5.2395e-030.3257image


Top

6. Enriched editing regions and immune gene sets for NDUFC2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000151366.11,NDUFC2BLCAEAG5.9659e-040.18011.0528e-030.17204.2944e-030.15023.2190e-020.1129image
chr11:78068485-78069212:-GBMEER5.4586e-06-0.34468.3782e-05-0.30051.4219e-04-0.29114.8634e-02-0.1533image
ENSG00000151366.11,NDUFC2GBMEAG5.4586e-06-0.34468.3782e-05-0.30051.4219e-04-0.29114.8634e-02-0.1533image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr11:78068485-78069212:-ACCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.0240e-020.2625image
ENSG00000151366.11,NDUFC2ACCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.0240e-020.2625image
chr11:78068485-78069212:-BLCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.3280e-050.2092image
ENSG00000151366.11,NDUFC2BLCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.2297e-070.2608image
chr11:78068485-78069212:-BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.6154e-440.4088image
ENSG00000151366.11,NDUFC2BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.6154e-440.4088image
chr11:78068485-78069212:-CESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER8.5847e-050.2346image
ENSG00000151366.11,NDUFC2CESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG8.5847e-050.2346image
ENSG00000151366.11,NDUFC2COADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG5.9381e-06-0.2842image
chr11:78068485-78069212:-COADGSVA_HALLMARK_BILE_ACID_METABOLISMEER7.8243e-05-0.2496image
chr11:78068485-78069212:-DLBCGSVA_HALLMARK_MYC_TARGETS_V2EER2.4874e-020.3543image
ENSG00000151366.11,NDUFC2DLBCGSVA_HALLMARK_MYC_TARGETS_V2EAG2.4874e-020.3543image
ENSG00000151366.11,NDUFC2ESCAGSVA_HALLMARK_BILE_ACID_METABOLISMEAG2.8616e-02-0.1837image
chr11:78068485-78069212:-ESCAGSVA_HALLMARK_BILE_ACID_METABOLISMEER2.8616e-02-0.1837image
chr11:78068485-78069212:-GBMGSVA_HALLMARK_GLYCOLYSISEER6.7779e-04-0.2612image
ENSG00000151366.11,NDUFC2GBMGSVA_HALLMARK_GLYCOLYSISEAG6.7779e-04-0.2612image
chr11:78068485-78069212:-HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.6936e-060.2266image
ENSG00000151366.11,NDUFC2HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.6936e-060.2266image
ENSG00000151366.11,NDUFC2KICHGSVA_HALLMARK_APOPTOSISEAG5.2273e-03-0.3533image
ENSG00000151366.11,NDUFC2KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.4838e-040.1937image
chr11:78068485-78069212:-KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.4838e-040.1937image
chr11:78068485-78069212:-KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEER2.4129e-02-0.1367image
ENSG00000151366.11,NDUFC2KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.3484e-02-0.1373image
ENSG00000151366.11,NDUFC2LAMLGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG1.7216e-030.5175image
chr11:78068485-78069212:-LGGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.0206e-170.3550image
ENSG00000151366.11,NDUFC2LGGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.0206e-170.3550image
ENSG00000151366.11,NDUFC2LIHCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG1.8458e-070.2663image
chr11:78068485-78069212:-LIHCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER1.8458e-070.2663image
ENSG00000151366.11,NDUFC2LUADGSVA_HALLMARK_G2M_CHECKPOINTEAG8.2455e-110.2938image
chr11:78068485-78069212:-LUADGSVA_HALLMARK_G2M_CHECKPOINTEER8.3464e-110.2937image
chr11:78068485-78069212:-LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.7278e-040.1643image
ENSG00000151366.11,NDUFC2LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG6.7278e-040.1643image
ENSG00000151366.11,NDUFC2OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.0271e-050.2558image
chr11:78068485-78069212:-OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.0645e-050.2554image
chr11:78068485-78069212:-PAADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER4.2690e-04-0.2665image
ENSG00000151366.11,NDUFC2PAADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG4.2690e-04-0.2665image
chr11:78068485-78069212:-PCPGGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER4.7053e-04-0.2559image
ENSG00000151366.11,NDUFC2PCPGGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG4.7053e-04-0.2559image
chr11:78068485-78069212:-PRADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.0051e-060.1990image
ENSG00000151366.11,NDUFC2PRADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG8.0051e-060.1990image
chr11:78068485-78069212:-READGSVA_HALLMARK_PROTEIN_SECRETIONEER8.3019e-03-0.2751image
ENSG00000151366.11,NDUFC2READGSVA_HALLMARK_PROTEIN_SECRETIONEAG8.3019e-03-0.2751image
ENSG00000151366.11,NDUFC2SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG6.7892e-060.2825image
chr11:78068485-78069212:-SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.7892e-060.2825image
chr11:78068485-78069212:-SKCMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.6649e-060.2289image
ENSG00000151366.11,NDUFC2SKCMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.6649e-060.2289image
chr11:78068485-78069212:-STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.8373e-040.1982image
ENSG00000151366.11,NDUFC2STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.7567e-040.1986image
ENSG00000151366.11,NDUFC2TGCTGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG2.4639e-06-0.3861image
chr11:78068485-78069212:-TGCTGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER2.4639e-06-0.3861image
ENSG00000151366.11,NDUFC2THCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG4.5624e-090.2579image
chr11:78068485-78069212:-THCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER4.5624e-090.2579image
chr11:78068485-78069212:-THYMGSVA_HALLMARK_MITOTIC_SPINDLEEER1.5182e-07-0.4608image
ENSG00000151366.11,NDUFC2THYMGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.5182e-07-0.4608image
chr11:78068485-78069212:-UCECGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER3.7072e-04-0.2715image
ENSG00000151366.11,NDUFC2UCECGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG7.0813e-04-0.2572image
ENSG00000151366.11,NDUFC2UCSGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.4861e-030.3834image
chr11:78068485-78069212:-UVMGSVA_HALLMARK_PROTEIN_SECRETIONEER4.7067e-03-0.3295image
ENSG00000151366.11,NDUFC2UVMGSVA_HALLMARK_PROTEIN_SECRETIONEAG4.7067e-03-0.3295image


Top

7. Enriched editing regions and drugs for NDUFC2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000151366.11,NDUFC2ACCABT.263EAG1.9111e-030.3461image
chr11:78068485-78069212:-ACCABT.263EER1.9111e-030.3461image
chr11:78068485-78069212:-BLCAKU.55933EER5.6591e-06-0.2366image
ENSG00000151366.11,NDUFC2BLCAKU.55933EAG6.3869e-07-0.2588image
chr11:78068485-78069212:-BRCAJNK.Inhibitor.VIIIEER1.5998e-11-0.2043image
ENSG00000151366.11,NDUFC2BRCAJNK.Inhibitor.VIIIEAG1.5998e-11-0.2043image
chr11:78068485-78069212:-CESCGefitinibEER3.3960e-05-0.2472image
ENSG00000151366.11,NDUFC2CESCGefitinibEAG3.3960e-05-0.2472image
chr11:78068485-78069212:-CHOLAKT.inhibitor.VIIIEER1.8480e-03-0.5077image
ENSG00000151366.11,NDUFC2CHOLAKT.inhibitor.VIIIEAG1.8480e-03-0.5077image
ENSG00000151366.11,NDUFC2COADGSK.650394EAG7.4850e-050.2498image
chr11:78068485-78069212:-COADAKT.inhibitor.VIIIEER5.0947e-060.2867image
chr11:78068485-78069212:-DLBCEHT.1864EER2.9046e-020.3454image
ENSG00000151366.11,NDUFC2DLBCEHT.1864EAG2.9046e-020.3454image
chr11:78068485-78069212:-ESCAAZD.0530EER2.7607e-02-0.1849image
ENSG00000151366.11,NDUFC2ESCAAZD.0530EAG2.7607e-02-0.1849image
ENSG00000151366.11,NDUFC2GBMBMS.754807EAG2.3874e-050.3216image
chr11:78068485-78069212:-GBMBMS.754807EER2.3874e-050.3216image
chr11:78068485-78069212:-HNSCCI.1040EER8.1079e-07-0.2458image
ENSG00000151366.11,NDUFC2HNSCCI.1040EAG8.1079e-07-0.2458image
ENSG00000151366.11,NDUFC2KICHKIN001.135EAG2.8514e-02-0.2806image
chr11:78068485-78069212:-KIRCABT.888EER2.1568e-05-0.2166image
ENSG00000151366.11,NDUFC2KIRCABT.888EAG2.1568e-05-0.2166image
ENSG00000151366.11,NDUFC2KIRPKIN001.135EAG1.6308e-040.2267image
chr11:78068485-78069212:-KIRPKIN001.135EER1.7631e-040.2255image
ENSG00000151366.11,NDUFC2LAMLEmbelinEAG9.7587e-040.5401image
chr11:78068485-78069212:-LGGAS601245EER5.3934e-17-0.3536image
ENSG00000151366.11,NDUFC2LGGAS601245EAG5.3934e-17-0.3536image
ENSG00000151366.11,NDUFC2LIHCAUY922EAG5.0223e-080.2779image
chr11:78068485-78069212:-LIHCAUY922EER5.0223e-080.2779image
ENSG00000151366.11,NDUFC2LUADDoxorubicinEAG8.4133e-07-0.2249image
chr11:78068485-78069212:-LUADDoxorubicinEER8.5374e-07-0.2248image
chr11:78068485-78069212:-LUSCGefitinibEER4.0407e-07-0.2431image
ENSG00000151366.11,NDUFC2LUSCGefitinibEAG4.0407e-07-0.2431image
ENSG00000151366.11,NDUFC2OVCHIR.99021EAG6.7464e-040.1985image
chr11:78068485-78069212:-OVCHIR.99021EER6.5739e-040.1989image
chr11:78068485-78069212:-PAADAZD6482EER1.0874e-040.2976image
ENSG00000151366.11,NDUFC2PAADAZD6482EAG1.0874e-040.2976image
chr11:78068485-78069212:-PCPGAZD6244EER7.2215e-04-0.2477image
ENSG00000151366.11,NDUFC2PCPGAZD6244EAG7.2215e-04-0.2477image
chr11:78068485-78069212:-PRADABT.888EER3.6427e-05-0.1845image
ENSG00000151366.11,NDUFC2PRADABT.888EAG3.6427e-05-0.1845image
ENSG00000151366.11,NDUFC2SARCCisplatinEAG9.9520e-08-0.3317image
chr11:78068485-78069212:-SARCCisplatinEER9.9520e-08-0.3317image
chr11:78068485-78069212:-SKCMLapatinibEER3.5964e-050.1983image
ENSG00000151366.11,NDUFC2SKCMLapatinibEAG3.5964e-050.1983image
chr11:78068485-78069212:-STADGefitinibEER8.4100e-03-0.1480image
ENSG00000151366.11,NDUFC2STADGefitinibEAG7.9770e-03-0.1490image
chr11:78068485-78069212:-TGCTBryostatin.1EER5.8190e-060.3726image
ENSG00000151366.11,NDUFC2TGCTBryostatin.1EAG5.8190e-060.3726image
ENSG00000151366.11,NDUFC2THCAEmbelinEAG9.5031e-190.3806image
chr11:78068485-78069212:-THCAEmbelinEER9.5031e-190.3806image
chr11:78068485-78069212:-THYMDoxorubicinEER8.8918e-110.5524image
ENSG00000151366.11,NDUFC2THYMDoxorubicinEAG8.8918e-110.5524image
ENSG00000151366.11,NDUFC2UCECLenalidomideEAG1.6190e-08-0.4164image
chr11:78068485-78069212:-UCECLenalidomideEER5.4337e-08-0.4044image
ENSG00000151366.11,NDUFC2UCSCisplatinEAG1.5198e-02-0.3382image
chr11:78068485-78069212:-UVMEmbelinEER2.0233e-040.4245image
ENSG00000151366.11,NDUFC2UVMEmbelinEAG2.0233e-040.4245image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType
chr11:78068485-78069212:-ENST00000281031.4O95298DB00157NADHSmallMoleculeDrug
chr11:78068485-78069212:-ENST00000281031.4O95298DB01136CarvedilolSmallMoleculeDrug
chr11:78068485-78069212:-ENST00000527806.1O95298DB00157NADHSmallMoleculeDrug
chr11:78068485-78069212:-ENST00000527806.1O95298DB01136CarvedilolSmallMoleculeDrug